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SObjective: The purpose of this study was to compare the outcomes and local control rates of patients with
peripheral T1 and T2 non–small-cell lung cancer treated with stereotactic body radiation therapy.
Methods: The records of 40 consecutive patients treated with 3- or 5-fraction lung stereotactic body radiation
therapy for peripheral, clinical stage I non–small-cell lung cancer were reviewed. Stereotactic body radiation ther-
apy was delivered at a median dose of 60 Gy. Doses to organs at risk were limited based on the Radiation Therapy
Oncology Group 0236 treatment protocol. Patients were staged clinically. Median follow was 12.5 months.
Results: Twenty-seven (67%) patients and 13 (33%) patients had T1 and T2 tumors, respectively. Thirty-seven
(94%) patients were medically inoperable. Nine (23%) patients had chest wall pain after stereotactic body radi-
ation therapy. Symptomatic pneumonitis developed in 4 (10%) patients. Increasing tumor size correlated with
worse local control and overall survival. The median recurrence-free survival for T1 and T2 tumors was 30.6
months (95% confidence interval [CI], 26.9–34.2) and 20.5 months (95% CI, 14.3–26.5), respectively
(P¼ .038). Local control at 2 years was 90% and 70% in T1 and T2 tumors, respectively (P¼ .03). The median
survival for T1 and T2 tumors was 20 months (95% CI, 20.1–31.6) and 16.7 months (95% CI, 10.8–21.2), re-
spectively (P ¼ .073).
Conclusions: Stereotactic body radiation therapy for T2 non–small-cell lung cancer has a higher local recurrence
rate and trended toward a worse survival than did T1 lesions. Tumor size is an important predictor of response to
stereotactic body radiation therapy and should be considered in treatment planning. (J Thorac Cardiovasc Surg
2010;140:583-9)INTRODUCTION
Early-stage (T1-2 N0) primary non–small-cell lung cancer
(NSCLC) traditionally has been managed with surgical
resection. Anatomic surgical resection, usually with a lobec-
tomy, for these early-stage tumors has resulted in 3- to
5-year survivals of 60% to 80%.1,2 Unfortunately,
significant complications are associated with lobectomy in
elderly patients or those with medical comorbidities such
as poor pulmonary reserve or cardiovascular disease.3,4
More limited surgical procedures (wedge resection or
segmentectomy) may be used but are associated with
poorer outcomes than are definitive surgical procedures.5
Historically, external beam radiation therapy has been
used as a primary treatment modality for patients with
early-stage NSCLC who are not operative candidates. This
standard 3-dimensional conformal therapy approach uses
small daily fractions of radiation of 1.8 to 2 Gy for a totale Departments of Surgeryb and Radiation Oncology,a University of Virginia,
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The Journal of Thoracic and Cadose of 50 to 66 Gy. Suboptimal 5-year survivals of 10%
to 30% (median survival, 12–16 months) and 5-year local
control rates of 50% to 70% have been reported with this
technique.6,7
The recognition that dose escalation is an important com-
ponent for improved tumor control led to the development of
stereotactic body radiation therapy (SBRT). SBRT uses ele-
ments of 3-dimensional conformal therapy combined with
stereotactic tumor localization to deliver significantly higher
daily doses of radiation while limiting radiation dose to the
surrounding normal tissues. Results from North America
and Europe have shown 3-year local control rates of 70%
to 90% with 2-year survivals of approximately 50%.8-10
Intuitively, tumor size would be expected to be an
independent predictor of local failure. Prior prospective
studies using lung SBRT failed to show any difference in
local control or median survival based on tumor
T staging.11 The purpose of this study was to determine
how tumor T stage affects the overall survival and local con-
trol rates in patients treated with lung SBRT for early-stage
NSCLC.METHODS
Patient Eligibility and Characteristics
Between March 2005 and January 2008, 60 patients with primary
NSCLC were treated with SBRT at the University of Virginia after institu-
tional review board approval for an institutional protocol. Forty patientsrdiovascular Surgery c Volume 140, Number 3 583
Abbreviations and Acronyms
BED ¼ biologic equivalent dose
CI ¼ confidence interval
CT ¼ computed tomography
FDG ¼ fluorodeoxyglucose
GTV ¼ gross tumor volume
HR ¼ hazard ratio
NSCLC ¼ non–small-cell lung cancer
PET ¼ positron emission tomography
PTV ¼ planning target volume
SBRT ¼ stereotactic body radiation therapy
SUV ¼ standardized uptake value
V20 ¼ volume of lung receiving 20 Gy
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Swith peripheral primary NSCLC were identified and reviewed. Peripheral
tumors were defined by the Radiation Therapy Oncology Group protocols
as the primary tumor not touching a volume 2 cm in all directions around
the proximal bronchial tree (distal 2 cm of the trachea, main stem bronchi,
and lobar bronchi). The median patient age was 73 years (range, 54–87
years). All patients were required to undergo computed tomography (CT)
of the chest and abdomen for clinical staging. No patients in our cohort
underwent mediastinoscopy or endobronchial ultrasound owing to medical
comorbidities. On the basis of CT imaging, patients were classified as hav-
ing clinical stage I (T1-2 N0) according to the American Joint Committee on
Cancer staging. Positron emission tomography (PET)–CT scans were ob-
tained as part of the initial staging workup in 34 (85%) patients. Histologic
confirmation of cancer was obtained in all patients by either tissue biopsy or
cytology. Patients with abnormal fluorodeoxyglucose (FDG) uptake (max-
imum standardized uptake value [SUV]>2.5) in the mediastinum were not
considered candidates for SBRT.
All patients were evaluated by a thoracic surgeon and radiation oncolo-
gist at our institution. Patients were treated with lung SBRT if they were
considered to be in medically inoperable condition or if they refused
surgery. Patients were considered to be medically inoperable owing to an
underlying physiologic condition prohibiting a potentially curable resection
based on a low probability of tolerating anesthesia, the operation, or the re-
covery period. Guidelines for inoperability were determined by the thoracic
surgeon and typically included a predicted postoperative forced expiratory
volume in 1 second of less than 30%, severely reduced diffusion capacity
greater 40% predicted, a performance status of 3 or greater, or severe
cardiac disease. No patients received prior lung irradiation.Pretreatment Assessment and Follow-up
Before SBRT was initiated, all patients underwent the following evalu-
ation: physical examination, weight and performance status assessment,
pulmonary function tests, and CT scan of the chest. After SBRT, follow-
up was performed approximately 4 to 8 weeks after treatment and approx-
imately every 3 months thereafter. CT of the chest was routinely obtained at
3-month intervals from the completion of radiotherapy. PET–CT was not
routinely obtained before the initiation of therapy. Twelve patients under-
went pretreatment and posttreatment PET–CT scans. The median time
from the end of treatment until PET–CT acquisition was 9.8 months. Tumor
response was defined as a decrease in the maximum tumor diameter by 30%
on CT imaging or decrease in abnormal FDG uptake of the tumor by 20% as
measured by maximum SUV. Local tumor recurrence was defined as a 20%
increase in the largest tumor diameter on successive follow-up imaging at 3-
month intervals based on Response Evaluation Criteria in Solid Tumors
(RECIST).12 Lobar recurrences were defined as local recurrences. Local re-584 The Journal of Thoracic and Cardiovascular Surgcurrence as demonstrated by an increase in abnormal FDG uptake was re-
quired to correspond to an enlarging CT abnormality. Metastatic
recurrence was defined as both regional nodal recurrence (N1 or N2) and
distant systemic metastases. Distant recurrence was determined by imaging
(CT or PET) and not confirmed pathologically unless amenable to percuta-
neous biopsy. Toxicity was graded using the Common Toxicity Criteria for
Adverse Events (CTCAE v3.0).
SBRT Planning
All patients underwent treatment planning scans using free breathing he-
lical CT imaging. Patients were immobilized using a ‘‘frameless’’ semirigid
evacuated bag system (Vac-Lok; MEDTEC, Orange City, Iowa). An iso-
center was placed in the geometric center of the tumor. Isocenter coordinates
were used for daily alignment for subsequent treatments. The gross tumor
volume (GTV) was identified on each axial CT slice using pulmonary win-
dowing. Solid components and adjacent ground-glass opacity were included
in the volume. The clinical target volume was identical to the GTV. In pa-
tients who underwent pretreatment PET–CT scans, PET imaging was not
used for treatment planning purposes. The planning target volume (PTV)
was intended to account for setup variability and target motion. The volume
was designed by expanding the GTV 0.5 cm in the radial direction and 1.0
cm in the cranial–caudal direction to account for tumor motion during a nor-
mal respiratory cycle as determined by the Radiation Therapy Oncology
Group 0236 protocol. Normal tissue dose constraints were as follows: for
the heart, trachea, and ipsilateral bronchus, a 30-Gy maximum point dose;
for the esophagus, a 27-Gy maximum point dose; for the brachial plexus,
a 24-Gy maximum point dose; and for the spinal cord, an 18-Gy maximum
point dose.
Treatment planning was coordinated with both the thoracic surgeons and
the radiation oncologists and performed using Hi-Art Helical TomoTherapy
inverse planning software (Tomotherapy, Madison, Wis). Lung and bone
density corrections were used for planning. The dose was prescribed such
that 100% of the dose covered 95% of the PTV. The median prescribed
dose in our cohort was 60 Gy (range, 42–60 Gy) in 3 to 5 fractions. The
median biologic equivalent dose (BED) for the cohort was 150 Gy (range,
78–180 Gy). The selection of total doses and fractionation to the primary
tumor was determined by constraints to the adjacent normal tissues.
Figure 1 shows a typical SBRT treatment plan. The prescribed dose was
not dictated by T stage or tumor size. Successful planning attempted to
meet the following criteria: (1) conformality of the PTV as judged by the
volume of the prescription isodose to the PTV should be less than 1.2
with minor deviations occurring 1.2 to 1.4; (2) any dose greater than
105% of the prescription should fall within the PTV: (3) heterogeneity of
the PTV as judged by the dose to 5% of the PTV to the dose to 95% of
the PTV should be less than 1.2; (4) volume of lung receiving 20 Gy should
be less than 10% (V20).
Statistical Analysis
The follow-up was determined from the date of the final SBRT treatment
to calculate median follow-up and Kaplan–Meier outcome data including
local control and overall survival. SPSS (SPSS, Inc, Chicago, Ill) was
used for statistical analysis. Log–rank tests were used to compare outcome
data between T-stage groups. A Cox regression analysis was performed to
adjust outcomes based on patient-specific data using multiple variables
analyzed simultaneously.RESULTS
The patient and tumor characteristics are listed in Table 1.
The most common reason for inoperability was poor pulmo-
nary reserve, which was identified in 26 patients (median
forced expiratory volume in 1 second 33% of predicted, me-
dian diffusion capacity 30% of predicted). Other reasonsery c September 2010
FIGURE 1. Representative helical TomoTherapy SBRT treatment plan with isodose lines and corresponding BED.
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cluded severe coronary artery disease not amenable to revas-
cularization (3 patients) or cardiac dysfunction with an
ejection fraction less than 30% (5 patients) and a Karnofsky
performance status less than 70% (3 patients). Seventy per-
cent of patients were dependent on supplemental oxygen.
Three (8%) patients refused surgical management of their
disease including mediastinal staging with endobronchial ul-
trasound or mediastinoscopy. All patients completed in-
tended radiotherapy without interruption. The median
follow-up time for the entire cohort from the end of treat-
ment was 12.5 months (range, 2–35 months). There wasTABLE 1. Patient and tumor characteristics
Median age (y) 73 (54–87)
Median tumor diameter (cm) 2.3 (0.9–6.5)
Tumor stage
T1 27
T2 13
Median follow-up (mo) 12.5 (2.1–34.7)
T1 14.5 (3–34.7)
T2 11.2 (2.1–26)
P ¼ .25
Median total dose (Gy) 60 (42.5–60)
T1 60 (42.5–60)
T2 55 (45–60)
P ¼ .13
Median BED (Gy) 150 (78–180)
T1 150 (78.6–180)
T2 150 (85.5–180)
P ¼ .07
BED, Biologic equivalent dose.
The Journal of Thoracic and Cano statistical difference in follow-up, nominal radiation
dose, or BED between the patients with T1 and T2 tumors
(see Table 1).
The median tumor size was 23 mm (range, 9–50 mm) with
27 (67%) and 13 (33%) having T1 and T2 tumors, respec-
tively. All tumors were peripheral in the lung. The median
distance to the chest wall was 4 mm (range, 0–25 mm).
Twenty-six patients had primary tumors located in the upper
lobe of the lungs, 12 in the lower lobe, and 2 in the right mid-
dle lobe.
The median PTV was 39.8 mL (range, 7.98–47.0 mL) for
T1 tumors and 103 mL (range 40.5–196 mL) for T2 tumors.
Thirty-two (80%) patients meet plan criteria for conformal-
ity with an index less than 1.2. Eight (20%) patients were
considered to have minor deviations (conformality index
1.2–1.4). The mean conformality index was 1.17 (SD 
0.12). All plans met the criteria for heterogeneity with
a mean heterogeneity index of 1.06 (SD  0.04). The
mean V20 for the cohort was 8.08% (SD 3.4%). The me-
dian beam-on time per fraction was 22 minutes.
Toxicity data are listed in Table 2. Twenty-three percent of
patients (9/40) had chest wall pain. The median time to onset
of chest wall pain was 7.1 months (range, 0.6–32.3 months).
The median time to resolution of chest wall pain was 4.6
months (range, 0.7–10.5 months). Two (5%) patients were
identified as having a rib fracture as documented by chest
CT. The median time to diagnosis of rib fracture was 20.6
months (range, 8.9–33.3 months). Symptomatic pulmonary
complications (>grade 1) occurred in approximately 10%
of patients, with 1 patient having grade 3 and grade 4 pneu-
monitis. No treatment-related deaths occurred.rdiovascular Surgery c Volume 140, Number 3 585
TABLE 2. Toxicity data
No. (n ¼ 40)
Chest wall pain 9 (23%)
Rib fracture 2 (5%)
Pneumonitis 2
Grade 1 5 (12%)
Grade 2 1 (2%)
Grade 3 1 (2%)
Median (range)
Onset of pain (mo) 7.1 (0.6–32.3)
Time to rib fracture (mo) 20.6 (8.9–33.3)
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posttreatment PET–CT imaging, the median pretreatment
maximum SUV was 6.0 (range, 1.0–16.2). Sixty-six percent
(8/12) had a decrease in their 9-month posttreatment maxi-
mum SUV with a median value of 2.0 (range, 0–10.9).
The mean maximum SUV reduction was 56% (range,
18%–100%). Thirty-four percent of patients (4/12) had an
increase in their tumor posttreatment maximum SUV with
a mean increase of 38% (range, 24%–60%).
Seven (17%) patients had local tumor recurrence with or
without distant recurrence. Eight patients (stage T1 ¼ 5,
stage T2 ¼ 3) had distant recurrence, 2 of whom had docu-
mented local recurrence at the time of distant metastatic dis-
ease. Overall survival and local control (Figures 2 and 3)
were determined for the entire cohort. The overall local
control at 2 years for the entire cohort was 83%. TheFIGURE 2. Local control
586 The Journal of Thoracic and Cardiovascular Surgmean recurrence-free survival for the entire cohort was
27.1 months (95% confidence interval [CI], 22.6–31.6).
Differences in local control were evaluated on the basis of
tumor size and clinical T stage. Increasing size correlated
with increased local failure (hazard ratio [HR], 1.904;
95% CI, 1.130–3.210; P ¼ .016). Local control at 2 years
for T1 tumors was 90%, whereas local control was 70%
for T2 tumors (P ¼ .035). The median recurrence-free sur-
vival for T1 and T2 tumors was 30.6 months (95% CI,
26.9–34.2) and 20.5 months (95% CI, 14.3–26.5), respec-
tively (P ¼ .038). The mean time to local recurrence for
T1 and T2 tumors was 16 and 7.5 months, respectively. Lo-
cal control for both T-stage groups was independent of pa-
tient age (HR, 1.074; 95% CI, 0.950–1.214), tumor
histology (HR, 0.466; 95% CI, 0.044–4.928), pretreatment
or posttreatment PET SUV (HR, 0.996; 95% CI, 0.730–
1.395), total radiation dose (HR, 1.143; 95% CI, 0.734–
1.779), or BED (HR, 1.578; 95% CI, 0.78–3.863). The me-
dian survival for the entire cohort was 20.1 months (95%CI,
18.7–28.4). The 1- and 2-year survivals were 85% and
45%, respectively. Differences in overall survival were
evaluated on the basis of tumor size and clinical T stage. In-
creasing tumor size correlated with poorer overall survival
(HR, 1.720; 95% CI, 1.154–2.563; P ¼ .008). The median
survival for T1 and T2 tumors was 20 months (95% CI,
20.1–31.6 months) and 16.7 months (95% CI, 10.8–21.2
months), respectively (P ¼ .073). The 1- and 2-year sur-
vivals for T1 tumors were 87% and 55%, respectively.by T-stage grouping.
ery c September 2010
FIGURE 3. Overall survival by T-stage grouping.
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35%, respectively.
DISCUSSION
Lung tumor size is an important factor for predicting out-
comes with lung SBRT for medically inoperable patients. In
our series, increasing tumor size correlated with local failure.
Patients with T1 tumors had a 90% local control rate at 2
years whereas those with T2 disease had an inferior 2-year
local control rate of 70%. Small tumors (T1) also had a lon-
ger time to recurrence than did larger tumors (T2). Whether
superior local control translates into a survival benefit is un-
clear. Our series demonstrates poorer overall survival when
size was evaluated as a continuous variable. Smaller clinical
T stage showed an estimated trend toward improved sur-
vival, although it did not quite reach statistical significance
(P<.07), likely secondary to the small sample size and short
follow-up. Our median follow-up time was relatively short at
12.5 months with 3 patients whose follow-up period was less
than 4 months, which limits the capture of local and distant
failure. With longer follow-up, a more clear survival advan-
tage may be demonstrated with T1 tumors as more occult
metastases may present in patients with T2 tumors.
The treatment of primary NSCLC with SBRT has been ad-
vocated in medically inoperable patients. The local control
with lung SBRT has been shown to be equivalent to limited
surgical resection. The incidence of local recurrence after
limited surgical resection with either wedge resection orThe Journal of Thoracic and Casegmentectomy has been reported to range from 10% to
27% in published series.2-5,13,14 Surgical data have shown
that tumor T stage correlates with local failure, with most
recurrences occurring within the first 2 years after
resection.13,14 Published series using SBRT have reported
similar local recurrence ranging from 10% to 30% with
most recurrence occurring within the first year after
treatment.8-11,15-17 Our series parallels other published data
with an overall local recurrence rate of 17% at 2 years and
a mean time to recurrence of approximately 12 months.
Tumor dose may play an important role in tumor steriliza-
tion and thus translate into improved local control and sur-
vival. Phase I and II studies have shown local control rates
of 70% to 90% at 3 years and overall survivals of 50% to
60% using variable treatment regimens.8-11,15-17 Nominal
total dose may underrepresent the biologic effectiveness of
treatment; therefore, BED is often used as a surrogate to
describe tumor dose. Our institutional cohort was treated
with a median BED of 150 Gy (range, 78–180 Gy), which
corresponds to doses reported in other published series.
Initial studies from North America have advocated using
a dose of 60 to 66 Gy delivered in 3 fractions (BED, 180
Gy). Yet other institutions from Europe and Asia have
advocated using lower nominal doses of 45 Gy in 3
fractions (BED, 112.5 Gy), 50 Gy in 5 fractions (BED,
100 Gy), or 48 Gy in 4 fractions (105.6 Gy) with
equivalent outcomes to larger BED schedules.13-17 Smaller
fraction sizes may decrease rates of symptomaticrdiovascular Surgery c Volume 140, Number 3 587
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Spneumonitis, chest wall pain, rib fracture, or skin injury. Our
data also show acceptable tumor control with minimal
toxicity. Grade II and III pneumonitis was seen in only 2
patients with a mean V20 of 8%. The incidence of chest
wall pain was similar to that of other published reports,
and only 2 patients had rib fractures.9,10
The implications of inferior local control and possibly sur-
vival with larger tumors may greatly affect the treatment ap-
proach with lung SBRT. A phase I series from Indiana
University8 included tumors 7 cm or larger in greatest diam-
eter. The original study design included dose escalation to
determine the maximum tolerated dose, stratified by tumor
size (3 cm or>3 cm). The maximum tolerated dose for
small tumors was 60 Gy in 3 fractions, whereas the maxi-
mum tolerated dose for tumors 5 to 7 cm was 66 Gy in 3 frac-
tions. Local recurrence was observed most commonly at
fraction sizes less than 1200 cGy. There was no observed
difference in local control or toxicity between T1 and T2 tu-
mors, although the authors state the study was not powered
to detect a difference. A follow-up phase II study from the
University of Indiana11 included 34 T1 tumors and 36 T2 tu-
mors 7 cm or smaller. Small tumors were prescribed 60 Gy
in 3 fractions and large tumors were prescribed 66 Gy in 3
fractions. A median follow-up of 50.2 months trended
toward a worse survival for T2 tumors (24.5 months) com-
pared with T1 tumors (38.7 months), although the difference
was not significant statistically.
Chen and associates15 recently performed a retrospective
evaluation of the efficacy of dose-individualized stereotactic
body radiotherapy for patients with T1-3 NSCLC. A major-
ity of patients were in stage T1. Sixty-five patients received
71.8 to 115.2 Gy of BED in 3.6- to 8.0-Gy daily fractions.
No difference in local control or overall survival was seen
between patients with T1, T2, or T3 tumors.
Inoue and colleagues16 retrospectively reviewed clinical
outcomes for clinically diagnosed small primary lung can-
cers in medically inoperable patients. Primary lung cancer
was not confirmed pathologically. A total of 115 patients
were treated with SBRT using a total dose of 30 to 70Gy
in 2 to 10 fractions. Ninety-three percent of the patients
had T1 tumors. There was no observed difference in local tu-
mor response on the basis of tumor size. The 3-year overall
survival for tumors 20 mm or smaller was 89% versus 60%
for patients with tumors larger than 20 mm. This study sug-
gests improved clinical outcome for smaller lesions although
the authors point out this may partially be due to the inclu-
sion of nonmalignant lesions in the cohort.
The impact of larger (T2) tumors with regard to treatment
planning is currently unclear. Our data, as well as other
series, suggest increased local failure compared with T1 tu-
mors and possibly poorer overall survival. Dose and frac-
tionation selection in our cohort was not influenced by
tumor size but rather to limit treatment-related toxicity and
meet dose constraints to the normal adjacent structures.588 The Journal of Thoracic and Cardiovascular SurgAlthough our data show no significant correlation with total
dose or BED and local failure, dose escalation may be nec-
essary above 60 Gy. Initial work from Indiana University8,11
prescribed larger tumors (>7 cm) 66 Gy in 3 fractions,
corresponding to a BED of approximately 200 Gy. The
median fraction size in our cohort was 12 Gy,
corresponding to a BED of 150 Gy. This dose differential
may account for increased local failure for larger tumors in
our patients. Another possibility is to address microscopic
tumor extension. Prior studies have shown that CT
imaging underestimates tumor extension based on
pathologic correlates by as much as 12 mm.18 The standard
approach in lung SBRT is to make the clinical target volume
equivalent to the GTV, therefore specifically not targeting
microscopic disease. Although dose falloff is sharp with
SBRT, the beam penumbra is thought to be sufficient to ster-
ilize microscopic disease. This concept may need to be
reconsidered with larger tumor margins for treatment.
The detection of metastatic disease before treatment is im-
portant in predicting patient survival. In our series, medias-
tinal lymph node involvement was ruled out with enhanced
CT or PET–CT. The sensitivity and specificity of PET–CT
for detecting mediastinal lymph nodes has been reported
to be 84%.19 Studies have also suggested that mediastinal
nodal involvement may be higher in larger tumors.13,14,19
Clinical experience with lung SBRT in the treatment of
primary NSCLC has shown less than 5% of isolated N1
or N2 nodal failures in the PET–CT era,20 suggesting that
surgical staging is not required in this subset of inoperable
patients. Despite the potential utility of PET–CT for assess-
ing mediastinal lymph nodes, the lack of mediastinal surgi-
cal staging may affect patient survival and distant failure by
not detecting occult metastases. Thirty-four patients in our
cohort underwent clinical staging with PET–CT and 6 pa-
tients did not, potentially affecting detection of metastatic
disease at the time of treatment.
The utility of PET–CT scan with conventional radiother-
apy has been widely established in predicting treatment out-
come in NSCLC.21,22 Prospective studies have shown that
posttreatment PET scan is highly predictive of survival
compared with CT scans, tumor stage, or performance
status.23 In the setting of high doses per fraction, the PET re-
sponse after treatment is likely different compared with con-
ventional radiotherapy. Hoopes and associates24 treated 58
patients with SBRT for early-stage lung cancer with
SBRT. Twenty-eight patients had pretreatment and post-
treatment PET–CT imaging. Fourteen percent of patients
had percent abnormal activity in the primary tumor at 2 years
without evidence of regional or distant failure. The Univer-
sity of Pittsburgh recently reported that in 28 patients treated
with lung SBRT, persistently elevated FDG uptake was
common despite tumor regression.25 With a median
follow-up of 1 year, patients with stable disease had
a mean decrease in SUV of 28%, partial responders hadery c September 2010
Dunlap et al General Thoracic Surgery
G
T
Sa mean decrease of 48%, and complete responders had
a mean decrease of 94%. Our data show mixed posttreat-
ment SUV response after SBRT. Sixty-six percent of pa-
tients with pretreatment and posttreatment PET–CT had
a mean decrease in SUV of 56%, whereas 34% of our pa-
tients had a mean increase of 38%. There was no correlation
between local tumor control and posttreatment SUV, al-
though our findings are limited by the small number of pa-
tient with both pretreatment and posttreatment PET–CT.
The results of our SBRT study in patients with medically
inoperable early-stage NSCLC are clinically equivalent to
prior studies7-11,15-17 regarding local control and overall
survival. Our data suggest that increased tumor size predicts
local failure after SBRT. Similar to other single institutional
data,8,11,15,16 larger tumor size suggests a clinically
significant decrement in overall survival, although not
statistically significant. Although our study has inherent
limitations to retrospective studies, including selection bias
and a small sample size, the findings bring into question the
utility of SBRT for larger tumors. SBRT may not be an
adequate local therapy for T2 tumors and thus alternative
treatment modalities should be explored. Radiofrequency
ablation as a primary modality or in combination with
SBRT may overcome underlying biologic resistance and
sterilize microscopic disease. Similarly, combined modality
therapies such as concurrent chemotherapy or targeted
agents may be appropriate for larger tumors to improve
local control and overall survival.CONCLUSIONS
SBRT using helical, arc-based radiation therapy is a well-
tolerated and efficacious treatment for medically inoperable
patients with early-stage peripheral NSCLC. Increasing
tumor size correlates with poorer survival and local control.
Patients with T2 tumors have higher rates of local recurrence
than those with T1 tumors. Although not significant, T1
tumors trended toward improved overall survival. Tumor
size is likely a significant factor in treatment response and
may need to be taken into account during treatment plan-
ning. Options may include dose escalation, large treatment
margins to cover microscopic disease, or combined modality
therapies.
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